ESMO 2020: Research breakthrough offers new hope for high risk patients with HR+ breast cancer
A new treatment for breast cancer patients with hormone receptor (HR+) early stage disease who…
Browsing: ESMO 2020
ESMO 2020: Step forward in treatment for patients with newly diagnosed advanced ovarian cancer
Almost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated…
ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer
The CHRYSALIS study (NCT02609776) is evaluating amivantamab, a fully human bispecific antibody that targets epidermal…
ESMO 2020: No benefit for post-operative radiotherapy in non-small-cell lung cancer
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and…
ESMO 2020: First new drug in years reduces recurrence in high-risk hormone receptor positive early breast cancer
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients…
ESMO 2020: Sacituzumab govitecan-hziy extends survival in phase 3 ASCENT study of metastatic triple-negative breast cancer
The results from the confirmatory Phase 3 ASCENT study have been announced showing that sacituzumab…
ESMO 2020: New first-line treatment option for metastatic kidney cancer, according to results of phase 3 study
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment…
ESMO 2020: Increasing the effectiveness of cancer treatments: Anti-PD-L1 immunotherapy
An international research team of Tokyo Medical and Dental University (TMDU) and Harvard Medical School…
ESMO 2020: Access to cancer medicines and clinical trials show stark variations across Europe
Access to cancer medicines is highly unequal across Europe both for new drugs in development…
ESMO 2020: COVID-19 pandemic halts cancer care and damages oncologists’ wellbeing
Delays and cancellation of cancer treatments and other safety measures undertaken to minimise the risk…